Molecular and Genetic Clinical Diagnostics An Introduction to Use, Application, Technology and Coding February 16, 2011 1 Results For Life: The Value of Laboratory Medicine • Message – Laboratory medicine central to medical decisions – Laboratory medicine changes course of diagnosis, treatment, management • Audience – Congress, media, thought leaders • Tools – Briefings, OpEds, advertising 2 ACLA Members and Associate Members Associate Members ACLA Member Sponsors Aculabs Agendia Arista Laboratories ARUP Laboratories Aureon Laboratories Aurora Diagnostics Axial Biotech Berkeley Heartlab Biodesix BioReference Laboratories bioTheranostics CBLPath Clarient Cleveland Clinic Foundation CorePlus DaVita DCI Laboratory Genomic Health Genoptix GI Pathology, PLLC Joint Venture Hospital Labs Laboratory Corp of America Laboratory Partners Machaon Diagnostics Mayo Clinic MEDTOX Laboratories Meridian Laboratories Myriad Genetics NeoGenomics Laboratories NMS Labs PathNet Esoteric Lab Inst Pathology Associates Medical Laboratories Pathology PerkinElmer Genetics Precision Therapeutics Quest Diagnostics Incorporated RenaLab RedPath Integrated Pathology Satellite Laboratory Services Solstas Lab Partners Spectra Laboratories Tethys Bioscience TridentUSA Health Services Virco Lab XDx Abbott Molecular American Medical Technologists Aperio Cgate Health HillCo Health LipoScience McKesson Health Solutions-Adv Diagn. Mgt Roche Siemens Sysmex XIFIN 3 A revolution in science requires a revolution in thinking • What disease is • How to identify and treat disease • When it is best to take action • Which individuals are at risk • The size of the population we treat • The economics of utilization and health spending • The ability to reduce adverse events, side effects, inappropriate use 4 Because we know vastly more about disease… Diagnose more precisely More effective treatment Select specific treatment that best fits disease Avoid adverse drug reaction Improve utilization Predict risk before symptoms occur Earlier treatment Preventive action Manage more effectively Better timing Adjustments as disease changes 5 Today • The basics of genetic testing Presentation • The use and value of genetic testing – Personalized medicine – Pharmacogenomics – Emerging Technologies • Laboratory procedures and coding Speakers Vicky Pratt, Ph.D., FACMG, Quest Diagnostics Sherri Bale, Ph.D., FACMG, GeneDX Kaye Jones, MLS (ASCP), CPC, LabCorp 6 THE BASICS OF GENETIC TESTING Presented by Victoria Pratt, Ph.D., FACMG 7 One of the most fundamental “basics” • Diagnostic laboratory testing drives health decisions – 70% of healthcare decisions based on diagnostic data • Diagnostic data yields essential information – Helps identify trends for public health – Enables physicians to care for individual patients – Facilitates new test development • Continuum of diagnostic lab testing – From diagnosis to predictive and personalized medicine • Diagnostic data increasingly… – … is providing actionable insights physicians can use to improve patient healthcare outcomes 8 DNA » RNA » Protein DNA Cell membrane Nucleus DNA bases mRNA Chain of amino acids Gene Protein Ribosome 9 Gene Tests: Three Common Methods Mutation Absent Mutation Present Chromosome Cytogenetics DNA Molecular Genetics Protein Biochemical Genetics 10 Types of Mutations • Single nucleotide - traditional – – – – Missense Nonsense (creation of stop codon) Splicing Regulatory sequences (promoter, 3’ end) • Deletions/Insertions – copy number variants (CNVs) – In frame – frameshift • Expansions (triplet repeat disorders) • Epigenetic (methylation) • Translocations and inversions 11 Alleles Quiet! I’ll speak for both of us! Dominant Allele I’ll have to be in charge now! Normal Allele Recessive Allele Damaged Allele 12 Human Chromosomes 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X Y 13 Gene Mutations Mismatch Insertion Deletion Deletion 14 General Principles • Hereditary disorders can affect multiple organs • Penetrance can be influenced by modifiers: genes + environment • Complexity of mutational spectrum varies 15 Different Genes, Different Functions Bone Cell Pancreas Cell Brain Cell 16 Gene inheritance is complex Gene Changes in Cystic Fibrosis Mucus Production Gene Normal Mutation 1 Mutation 2 Mutation 3 No Symptoms Severe Symptoms Mild Symptoms No Symptoms 17 Continuum of Diagnostic Lab Testing Diagnostic Predictive Personalized Confirm diagnosis Identify higher chance for disease before symptoms Tailor drug treatment to genotype Example Example Example Cystic Fibrosis Huntington Disease HIV Therapy Physician Patient Pharma 18 Common genetic disorders • Inherited (predictive or diagnostic) – – – – Cystic fibrosis Thrombophilia Hereditary hemochromatosis Fragile X syndrome • Acquired (predictive or diagnostic) – Chronic myelogenous leukemia (CML) • Pharmacogenetics (personalized) – Cytochrome P450s – HLA 19 New Assay/Biomarker Progression Retrospective clinical trials CLINICAL RESEARCH Biomarker associated with disease Prospective clinical trials TEST TRANSLATION Lab test developed Analytical validation CLINICAL VALIDITY Test can predict clinical outcomes CLINICAL UTILITY Benefits patients 20 THE USE AND VALUE OF GENETIC TESTS FOR PATIENTS Presented by Sherri J Bale, Ph.D., FACMG Victoria Pratt, Ph.D., FACMG 21 Genetic Tests for Constitutional Mutations • Cytogenetic Tests • Molecular Tests 22 Cytogenetic Test • Standard karyotype, used to look for gross chromosomal anomalies in children with development delays, congenital anomalies, mental retardation • FISH, used to look at 1 or 2 specific chromosomal regions suspected by the physician • BAC arrays, used to look at many (100s) chromosomal regions at once, using FISH technology • CGH array, used to look at MANY (50K-200K) regions at once, and identify specifically which genes are involved in the chromosomal anomaly 23 Child with Multiple Congenital Anomalies and/or Autism Standard karyotype CGH array - “molecular karyotype” 24 Patient with Tetralogy of Fallot, Suspected 22q11 Deletion • FISH test, 2 probes: – – – – used in baby found deletion confirmed dx Provided prognostic info to family. • Parents tested by FISH: – Negative – Provided information re: risk in future children 25 Child with Multiple Anomalies and Autism; No Specific Syndrome Suspected • Karyotype normal • CGH array followed Karyotype. – Identified deletion involving end of one arm of chromosome 3 • Parents tested by FISH and dad found to be balanced carrier of the deletion • Prenatal diagnosis by quantitative PCR is now possible for the family. 26 Molecular Test – PCR, followed by sequencing, for identification of mutation • Used to identify mutation in a patient with inherited disease • Number of times PCR is done and how much sequencing is required depends on SIZE of gene, MANY UNITS. • Once mutation is identified, testing of parents, sibs, other relatives for ONLY that mutation, is needed. ONE or ONLY a FEW UNITS. 27 Molecular diagnosis of Gorlin Syndrome • 13 yo child presented to dentist with a jaw cyst – surgery performed but tooth was lost. Referred to geneticist. • Geneticist suspected Gorlin Syndrome • Molecular diagnosis involved PCR and sequencing, 26 “units” (large gene). Mutation identified. • Prognosis now known: This individual would develop many skin cancers, more jaw cysts. • Regular surveillance by dermatologist and dentist allowed early identification, less expensive treatment, and good clinical outcome: – Teeth were saved; Minimal damage to nose, ears, eyes 28 Use and Value of Genetic Tests • Diagnosis – Enables physicians to properly care for patient • Prognosis – Appropriate surveillance leading to early care and intervention • Risk Information – Is it inherited? What is the recurrence risk in future pregnancies? • Prenatal/Pre-symptomatic diagnosis – Allows informed decision making, preventive care 29 Personalized Medicine, Pharmacogenetics 30 Chronic Myelogenous Leukemia Science Patient Care Fusion of BCR/ABL genes Better response rates, less toxicity FISH, Quantitative PCR to identify Complete remission in many patients Treatable with Gleevac 5-year survival rate: 69% in 2001, 89% now Some patients become resistant to Gleevac Mutations in tyrosine kinase domains (DNA sequencing) 31 Clopidogrel (Plavix®) Science Patient Care To inhibit blood clots in coronary artery disease, peripheral artery disease, and cerebrovascular disease. Prevention of vascular ischemic events in patients with symptomatic artherosclerosis Metabolized by cytochrome P450 2C19 to active form Also used, along with aspirin, for preventing thrombosis after placement of intracoronary stent FDA: clopidogrel cannot be taken with Prilosec (omeprazole) and Nexium (esomeprazole) Inhibitors of 2C19 32 EMERGING TECHNOLOGIES AND TESTING Presented by Victoria Pratt, Ph.D., FACMG 33 The genome is complex • High throughput DNA sequencing • microRNAs • Copy Number Variants (CNVs) • Epigenetics – methylation • Proteomics – Up and down regulation – Disease-specific patterns 34 New high throughput DNA (NextGen) sequencing methods • Reduced the cost • Increased sequencing capacity • 454 (Roche) • Solexa (Illumina) • SOLiD (ABI) 35 MicroRNAs (miRNA) • Single-stranded RNA molecules – 21-23 nt – Transcribed from non-coding DNA • Regulate gene expression • Cancer – May enable classification of cancers (CUP = cancer of unknown primary) – Determine therapy 36 Copy Number Variants (CNVs) (Variome) • Large deletions or duplications of DNA – Usually cannot be detected by DNA sequencing – Newer technologies • aCGH • Impacts – – – – – Autism Alzheimer disease Parkinson disease susceptibility to HIV-1 some forms of color blindness 37 Epigenetics • Changes in chromatin structure (how DNA is packaged) or alters gene activity without changing the DNA – DNA methylation – Modification of histones – Position effects • Cancer and imprinting disorders 38 Genetic tests find mutations, not disease Chances of Developing Breast Cancer by Age 65 8 100 7 80 6 60 5 40 4 20 3 0 With BRCA 1 Gene Without BRCA 1 Gene 2 1 Normal BRCA1 0 Altered BRCA1 39 LABORATORY PROCEDURES AND CODING Presented by Kaye Jones, MLS(ASCP), CPC 40 Objective • To improve your understanding of current molecular diagnostic CPT coding 41 Molecular Codes • CPT codes 83890-83914 represent steps performed during molecular diagnostic procedures • CPT codes are assigned based on the different steps and the number of times each type of step is performed. • Example: 83898 Amplification x3 83896 Nucleic acid probe, each x25 42 Molecular Codes • Different molecular methods may be used for the same analyte • Those methods may vary among different laboratories. • Therefore, different labs may code their tests differently 43 Molecular Codes • No clear written guidelines for how to assign units of service • Example: When a Cystic Fibrosis procedure for 23 mutations is performed by two different labs – One lab bills for 23 probes (1 per mutation). – The other lab bills for 46 probes (2 per mutation because you need a normal and a mutant probe for each in order to interpret the assay). 44 Molecular Codes • All industry stakeholders recognize the issues surrounding the assignment and billing of molecular diagnostic procedures • A number of organizations and entities are engaged in a collaborative process to review and address coding issues in an effort to increase transparency 45 Cytogenetics • This is another area where CPT codes are assigned based on the procedural steps performed. • Routine chromosome analysis typically requires three steps to complete the procedure. – 88230 Tissue culture – 88262 Karyotyping – 88291 Interpretation and report with a picture of the actual chromosomes 46 Cytogenetics • Cytogenetic FISH is often necessary to diagnose constitutional defects • Cytogenetic FISH may also be a stand alone order necessary to evaluate leukemias such as CML and MM • Units of service are determined by the number of FISH probes and specific procedures needed to evaluate the cells 47 Molecular Diagnostics and Cytogenetics • Think of newer CGH procedure as a combination of molecular diagnostic procedural steps needed to prepare the patient’s sample, and the cytogenetic CGH chip analysis • There is much confusion within the industry regarding how to assign CPT codes to CGH procedures 48 Molecular Diagnostics and Cytogenetics • Array CPTs 88384-88386 are in the Surgical Pathology section of CPT. • These codes are – global codes with Technical and Professional components, – only represent the work needed for the array chip and I&R – sample preparation is coded with molecular diagnostic codes – only appropriate for when a physician/pathologist performs the I&R 49 Molecular and Cytogenetic Codes • In summary: – Molecular procedures are coded based on the procedural steps – Units of service are determined by the number of times each step is performed – Different procedures may exist for the same analyte, which makes the CPT coding different – Lack of standardized coding guidelines add to the complexities of how to assign CPTs 50 Thank you • For more information, contact: David Mongillo, Vice President for Policy and Medical Affairs American Clinical Laboratory Association dmongillo@clinical-labs.org 202-637-9466 51